SE7700971L - Kemisk forening for medicinska preparat samt forfarande for behandling av psoriasis hos varmboldiag djur med preparatet - Google Patents

Kemisk forening for medicinska preparat samt forfarande for behandling av psoriasis hos varmboldiag djur med preparatet

Info

Publication number
SE7700971L
SE7700971L SE7700971A SE7700971A SE7700971L SE 7700971 L SE7700971 L SE 7700971L SE 7700971 A SE7700971 A SE 7700971A SE 7700971 A SE7700971 A SE 7700971A SE 7700971 L SE7700971 L SE 7700971L
Authority
SE
Sweden
Prior art keywords
diag
psoriasis
animals
procedures
preparation
Prior art date
Application number
SE7700971A
Other languages
English (en)
Swedish (sv)
Inventor
K B Sloan
N S Bodor
Original Assignee
Inter Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inter Research Corp filed Critical Inter Research Corp
Publication of SE7700971L publication Critical patent/SE7700971L/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE7700971A 1976-02-06 1977-01-31 Kemisk forening for medicinska preparat samt forfarande for behandling av psoriasis hos varmboldiag djur med preparatet SE7700971L (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/655,786 US4061753A (en) 1976-02-06 1976-02-06 Treating psoriasis with transient pro-drug forms of xanthine derivatives

Publications (1)

Publication Number Publication Date
SE7700971L true SE7700971L (sv) 1977-08-07

Family

ID=24630341

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7700971A SE7700971L (sv) 1976-02-06 1977-01-31 Kemisk forening for medicinska preparat samt forfarande for behandling av psoriasis hos varmboldiag djur med preparatet

Country Status (11)

Country Link
US (1) US4061753A (OSRAM)
AU (1) AU506717B2 (OSRAM)
BE (1) BE851078A (OSRAM)
CA (1) CA1104569A (OSRAM)
DE (1) DE2705025A1 (OSRAM)
FR (1) FR2340318A1 (OSRAM)
GB (1) GB1576351A (OSRAM)
IL (1) IL51367A0 (OSRAM)
IN (1) IN146058B (OSRAM)
SE (1) SE7700971L (OSRAM)
ZA (1) ZA77621B (OSRAM)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275064A (en) * 1976-02-06 1981-06-23 Interx Research Corporation Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents
US4133893A (en) * 1977-05-26 1979-01-09 Calbiochem Behring Corp. Topical treatment of skin diseases
SE416810C (sv) * 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
DE2922159A1 (de) * 1979-05-31 1980-12-04 Boehringer Mannheim Gmbh Neue xanthin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GR75219B (OSRAM) * 1980-04-21 1984-07-13 Merck & Co Inc
US4341783A (en) * 1980-07-31 1982-07-27 Lemmon Company Topical use of dyphylline and dyphylline containing compositions
GB8501488D0 (en) * 1985-01-21 1985-02-20 Beecham Group Plc Treatment
IT1184139B (it) * 1985-01-23 1987-10-22 Proter Spa Composti ad attivita' mucolitica e broncodilatatrice,procedimento per la loro preparazione e composizioni farmaceutiche che licontengono come principi attivi
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4988702A (en) * 1986-08-26 1991-01-29 Warner-Lambert Company Novel 9-deazaguanines
US4921858A (en) * 1986-10-24 1990-05-01 Warner-Lambert Company 7-deazaguanines as immunomodulators
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
US5886162A (en) * 1989-11-03 1999-03-23 Research Foundation Of State University Of New York Lipophilic diakylaminomethylene prodrug derivatives for the inhibition of replication of viruses
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6117904A (en) * 1999-09-03 2000-09-12 Murphy; Donald M. Treatment of pruritus
US6541517B1 (en) * 1999-09-03 2003-04-01 Donald M. Murphy Treatment of skin disorders
SK288003B6 (sk) * 2001-02-24 2012-10-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthin derivatives, method for the preparation thereof, pharmaceutical composition containing thereof and their use
RU2196583C1 (ru) * 2001-05-29 2003-01-20 Барбинов Вячеслав Викторович Средство для наружной терапии псориаза и способ его изготовления
BR122012026540B8 (pt) * 2002-08-21 2021-05-25 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-il]-xantinas, seus sais farmacêuticamente aceitáveis, seu uso e seu processo de preparação, bem como medicamento e seu processo de preparação
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
MX2010001821A (es) * 2007-08-17 2010-03-10 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
ES2764251T3 (es) * 2008-08-15 2020-06-02 Boehringer Ingelheim Int Inhibidores de DPP-4 para uso en el tratamiento de curación de heridas en pacientes diabéticos
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1265879A (fr) * 1960-05-23 1961-07-07 Dérivés substitués en -7 de la théophylline et leurs procédés de préparation
DE1226587B (de) * 1962-07-05 1966-10-13 Josef Klosa Dipl Chem Dr Rer N Verfahren zur Herstellung neuer Theophyllinoaminosaeuren

Also Published As

Publication number Publication date
US4061753A (en) 1977-12-06
AU506717B2 (en) 1980-01-24
IN146058B (OSRAM) 1979-02-10
BE851078A (fr) 1977-05-31
DE2705025A1 (de) 1977-08-11
GB1576351A (en) 1980-10-08
AU2202577A (en) 1978-08-17
FR2340318A1 (fr) 1977-09-02
IL51367A0 (en) 1977-04-29
ZA77621B (en) 1977-12-28
CA1104569A (en) 1981-07-07

Similar Documents

Publication Publication Date Title
SE7700971L (sv) Kemisk forening for medicinska preparat samt forfarande for behandling av psoriasis hos varmboldiag djur med preparatet
Diller A model for cognitive retraining in rehabilitation.
SE414573B (sv) Medicinsk handske samt form for framstellning av handsken
SE418088B (sv) Med glyoxal behandlad akrylpolymer i finfordelad form samt motsvarande framstellningsforfarande
SE8000105L (sv) 2-penemforeningar samt forfarande for framstellning derav
NL7800178A (nl) Medisch gebruiksvoorwerp en werkwijze voor het vervaardigen daarvan.
NO146394C (no) Analogifremgangsmaate til fremstilling av 1,2-difenyl-3-(imidazol-1-yl)-propan-2-oler med terapeutisk virkning
NO146774C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazin- og piperidinderivater
NO790039L (no) 3-azolyl-benzotriazin og -benzotriazin-1-oksyd, fremgangsmaate til deres fremstilling samt deres anvendelse til bekjempelse av plantesykdommer
DK294180A (da) Hidtil ukendte carboxylsyrederivater deres fremstilling og anvendelse
SE428520B (sv) Forfarande for pigmentering av kottet hos anadromons fisk
NO810826L (no) Kosmetisk pust-oppfriskende og munnavkjoelende preparat, samt fremgangsmaate for anvendelse derav
NO781147L (no) Preparat for behandling av herpes zoster og andre herpes-infeksjoner samt fremgangsmaate for fremstilling av dette
NO151319C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive beta-mono-fluormetyl-beta-alanin- og beta-difluormetyl-beta-alanin-forbindelser
FI821035A7 (fi) Imidatso/1,2-a/pyrimidiinijohdannaiset, niiden valmistus ja käyttö tautien hoidossa.
NO802030L (no) Fremgangsmaate til fremstilling av mavesyrenoeytriliserende midler, mavesyrenoeytraliserende midler og en fremgangsmaate for behandling av hypersurhet og sykdommer forbundet med dette
SE7704309L (sv) Bestralningsapparat for behandling av hudsjukdomar
NO152771C (no) Fremgangsmaate for varmebehandling av nymelket melk samt varmebehandlingsanordning for samme.
IT1141392B (it) Procedimento di trasformazione dell'idrargillite in boemite
SE7800930L (sv) Forfarande for framstellning av bensensulfonamid- och bensenkarboxamidderivat med terapeutisk verkan
SE7806244L (sv) Foreningar i pregnanserien med syrefunktion i 19-stellning, forfarande for framstellning derav och farmaceutiska preparat innehallande dessa foreningar
IT1115363B (it) Amminoalcossibenzofurani,loro procedimento di preparazione e loro applicazione in terapia
NO801989L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidopyrimidiner
NO147440C (no) Ski med profilert loepeflate, samt fremgangsmaate og innretning for fremstilling av samme
DK99880A (da) Lege-og sportsanlaeg